Best Healthcare Companies in Suzhou, China
The 53 best Healthcare companies in Suzhou, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Virtue Diagnostics.
Ranked: Best Healthcare companies in Suzhou
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Arromax Pharmatech Manufacturer of oncology, cardiovascular and diabetes generics | — | — | Funding Raised | — | 2011 | Eric Hong CEO & GM | 20 patents Design and synthesis of heterocyclic small‑molecule kinase inhibitors (BTK, sodium channel, EP4). | — |
| 2 | Bichal Biological Technology Researching and manufacturing of APIs & Intermediates for pharma companies | — | — | Deadpooled | — | 2010 | Bison Zhang CEO | — | — |
| 3 | Bioworkshops Biologics contract development and manufacturing organization offering services for the development and… | — | — | Unfunded | — | 2019 | Alex Zhu CEO | — | — |
| 4 | crystal pharmatech Crystal Pharmatech is a solid-state drug development firm. | — | — | Private | 180 | 2010 | — | 234 patents Novel crystalline forms and salts of pharmaceutical active ingredients for improved drug properties. | — |
| 5 | Dawnrays Pharm Manufacturer of private label soft drinks and energy drinks | — | — | Public | 1,132 | 1995 | — | — | — |
| 6 | Iron-Tech Provider of intelligent management solutions for medical materials and healthcare service organizations | — | — | Funding Raised | — | 2006 | Li Xu CEO | — | — |
| 7 | Joekai Biotechonolgy Provider of preclinical services specialized fly(Drosophila)-based in vivo models for CNS drug development | — | — | Deadpooled | — | 2011 | Jian Chen CEO | — | — |
| 8 | KCI Provider of preclinical pathology & imaging services | — | — | Unfunded | — | 2014 | Zhuang Yongjie Founder & CEO | — | — |
Top 12 Healthcare companies in Suzhou
#1
Series C · Suzhou, Jiangsu · founded 2001 · 559 employees$80Mraised▾
Manufacturer of pharmaceutical formulations, active pharmaceutical ingredients, and veterinary drugs. The company develops and produces a range of pharmaceutical products, including formulations for human use and active pharmaceutical ingredients. It also offers products related to veterinary medicine. A robust research and development system supports innovation and quality control throughout the production process. The company maintains comprehensive production and quality systems.
- Mar 2026Series C—
- Jan 2019Series C$80M
#2
Series C · Suzhou, Jiangsu · founded 2015$15.8Mraised▾
Developer of stem cell therapy products and human organ regenerative medicine. The company is mainly engaged in research and development of regenerative medicine, providing users with interstitial lung disease, assisted reproduction, stem cell storage and chronic obstructive pulmonary disease treatment solutions.
- Feb 2026Series C$50.6M
- Mar 2022Series B$15.8M
#3
Series B · Suzhou, Jiangsu · founded 2018 · 80 employees$13.8Mraised▾
Provider of R&D, production, sales, technical, and consultation services for medical X-ray tubes
- Jan 2026Series A$14.4M
- Jul 2023Series B$13.8M
- Sep 2021Seed—
#4
Series B · Suzhou, Jiangsu · founded 2019 · 500 employees$130Mraised▾
Provider of an in vitro assay platform for diagnostic solutions. The company's technology can be used for early screening, diagnosis, treatment/monitoring and management of the minimal residual disease. The technology can be used in a variety of diseases such as infectious disease, cancer, maternal and fetal health, and chronic disease.
- Jan 2022Series B$100M
- Dec 2020Series A$30M
#5
Series B · Suzhou, Jiangsu · founded 2018$80Mraised▾
Provider of cell & gene therapy, discovery research, analytical development, and testing services
- Aug 2022Series B$80M
#6
Series C · Suzhou, Jiangsu · founded 2018 · 100 employees$74Mraised▾
Researcher and developer of biological and pharmaceutical solutions. The company, as a contract development and manufacturing organization (CDMO), is equipped with professional technology platforms such as protein science, cell engineering, cell culture, protein purification, analytical science, formulation development, preparation technology, as well as pilot plant, GMP workshop, aseptic preparation filling line, preparation freeze-drying production line and so on, providing clients with one-stop biopharmaceutical development and production services.
- Aug 2022Series C$74M
- Dec 2020Series A—
#7
Public · Suzhou, Jiangsu · founded 2007 · 488 employees$13.7Mraised▾
IVD products for clinical immune diagnosis
- Nov 2023Post IPO$13.7M
#8
Series B · Suzhou, Jiangsu · founded 2017$50Mraised▾
Developer of small molecule innovative drugs designed for inflammatory, autoimmune diseases and cancer. The company focuses on the molecular mechanism of regulated cell death and the related pathogenesis in human diseases, improving the current therapeutic standard of targeted disease areas.
#9
Series B · Suzhou, Jiangsu · founded 2013$51.3Mraised▾
Developer of diagnostic products
- Sep 2020Series B$51.3M
#10
Series B · Suzhou, Jiangsu · founded 2009 · 437 employees$60Mraised▾
Developer of antibody and protein-based biopharmaceuticals. It develops and manufactures biopharmaceuticals, encompassing both innovative drugs and biosimilars. A complete research and development platform is utilized, covering all stages from early screening to clinical trials and regulatory submissions. The company also provides technology transfer to other pharmaceutical companies, supporting broader industry advancement. Its focus is on delivering advanced therapies to patients.
- May 2019Series B$60M
#11
Series B · Suzhou, Jiangsu · founded 2009 · 843 employees$61.9Mraised▾
Suzhou Zelgen Biopharmaceuticals (Zelgen) is focusing on developing small as well as large molecules. Zelgen has two subsidiary companies, Shanghai Zelgen Pharma and Suzhou Zelgen Biosciences working on small molecules & recombinant protein drug discovery respectively. The company has developed small molecules such as Donafenib (Zepsun®), Jaktinib, ZG0320, ZG5216 and ZG0128 (few are based on drug stabilization technology). It also has four recombinant protein drugs under development, including rhThrombin(Zepning®), ZG001, ZG002, and ZG003. Donafenib is a lead molecule for late-stage cancer is in clinical trial phase III & Jaktinib is in phase I for autoimmune disease & cancer. A recombinant protein drug lead, rhThrombin is in phase I clinical trial for surgical bleeding.
- Jan 2018Series B$61.9M
#12
Series A · Suzhou, Jiangsu$15.7Mraised▾
Provider of drug research and development services for pharmaceutical sector
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.